Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:50 ET | 500 | 1.545 |
09:59 ET | 200 | 1.5338 |
10:06 ET | 1000 | 1.5434 |
10:08 ET | 2524 | 1.56 |
10:10 ET | 400 | 1.5305 |
10:14 ET | 2653 | 1.58 |
10:48 ET | 100 | 1.58 |
11:04 ET | 2000 | 1.56 |
11:22 ET | 5024 | 1.56 |
11:24 ET | 5506 | 1.56 |
11:31 ET | 370 | 1.58 |
12:14 ET | 1500 | 1.566 |
01:21 ET | 200 | 1.585 |
01:32 ET | 100 | 1.57 |
01:44 ET | 1887 | 1.56 |
01:55 ET | 121 | 1.56 |
03:27 ET | 150 | 1.56 |
03:39 ET | 500 | 1.57 |
03:45 ET | 400 | 1.5899 |
03:56 ET | 100 | 1.58 |
03:59 ET | 2557 | 1.56 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 55.0M | -4.5x | --- |
CASI Pharmaceuticals Inc | 44.2M | -1.4x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Marinus Pharmaceuticals Inc | 73.1M | -0.5x | --- |
Biofrontera Inc | 5.4M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.0M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.